Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myeloma X Relapse Intensive: second autologous transplant versus weekly cyclophosphamide after PAD re-induction
ISRCTN60123120Phase 3Completed
- Sponsor
- Leeds Teaching Hospitals NHS Trust
- Start
- Sep 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of melphalan, cyclophosphamide, bortezomib, doxorubicin and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Leeds Teaching Hospitals NHS Trust. Primary endpoint: Time to disease progression. Started Sep 2007; status: completed.
02
Drugs
melphalancyclophosphamidebortezomibdoxorubicindexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN60123120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN60123120.